Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer

被引：46
作者：
Mbese, Zintle [1 ]
Aderibigbe, Blessing A. [1 ]
机构：
[1] Univ Ft Hare, Dept Chem, Alice Campus, ZA-5700 Alice, South Africa
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2021年 / 22卷 / 13期
基金：
新加坡国家研究基金会;
关键词：
Osteoporosis; bisphosphonates; bone cancer; metastatic cancer; CELL LUNG-CANCER; SKELETAL-RELATED EVENTS; ZOLEDRONIC-ACID; BREAST-CANCER; IN-VITRO; MULTIPLE-MYELOMA; DOUBLE-BLIND; DISEASE; PROSTATE; DRUG;
D O I：
10.3390/ijms22136869
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Metastatic bone cancer occurs in every type of cancer but is prevalent in lung, breast, and prostate cancers. These metastases can cause extensive morbidity, including a range of skeletal-related events, often painful and linked with substantial hospital resource usage. The treatment used is a combination of chemotherapy and surgery. However, anticancer drugs are still limited due to severe side effects, drug resistance, poor blood supply, and non-specific drug uptake, necessitating high toxic doses. Bisphosphonates are the main class of drugs utilized to inhibit metastatic bone cancer. It is also used for the treatment of osteoporosis and other bone diseases. However, bisphosphonate also suffers from serious side effects. Thus, there is a serious need to develop bisphosphonate conjugates with promising therapeutic outcomes for treating metastatic bone cancer and osteoporosis. This review article focuses on the biological outcomes of designed bisphosphonate-based conjugates for the treatment of metastatic bone cancer and osteoporosis.
引用
收藏
页数：21
相关论文
共 50 条
[31]   Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial [J].
van Hellemond, Irene E. G. ;
Smorenburg, Carolien H. ;
Peer, Petronella G. M. ;
Swinkels, Astrid C. P. ;
Seynaeve, Caroline M. ;
van der Sangen, Maurice J. C. ;
Kroep, Judith R. ;
de Graaf, Hiltje ;
Honkoop, Aafke H. ;
Erdkamp, Frans L. G. ;
van den Berkmortel, Franchette W. P. J. ;
de Roos, Wilfred K. ;
Linn, Sabine C. ;
Imholz, Alexander L. T. ;
de Boer, Maaike ;
Tjan-Heijnen, Vivianne C. G. .
BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) :675-685
[32]   Contemporary Therapeutic Approaches Targeting Bone Complications in Prostate Cancer [J].
Lee, Richard J. ;
Saylor, Philip J. ;
Smith, Matthew R. .
CLINICAL GENITOURINARY CANCER, 2010, 8 (01) :29-36
[33]   A Conjugate of Gemcitabine With Bisphosphonate (Gem/BP) Shows Potential as a Targeted Bone-Specific Therapeutic Agent in an Animal Model of Human Breast Cancer Bone Metastases [J].
El-Mabhouh, A. A. ;
Nation, P. N. ;
Abele, J. T. ;
Riauka, T. ;
Postema, E. ;
McEwan, A. J. B. ;
Mercer, J. R. .
ONCOLOGY RESEARCH, 2011, 19 (06) :287-295
[34]   Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer [J].
D'Oronzo, Stella ;
Silvestris, Erica ;
Paradiso, Angelo ;
Cives, Mauro ;
Tucci, Marco .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (08)
[35]   The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents-part 3: prostate cancer [J].
Patel, Vinod ;
Burns, Megan ;
Patel, Sheelen ;
Grossman, Sanford ;
Wali, Rana ;
Sassoon, Isabel ;
Pintus, Elias ;
Henien, Marianne .
BRITISH DENTAL JOURNAL, 2022,
[36]   Long-term safety and efficacy of bisphosphonate therapy in advanced lung cancer with bone metastasis [J].
Wei, Zixin ;
Pan, Bo ;
Jia, Dexin ;
Yu, Yan .
FUTURE ONCOLOGY, 2022, 18 (18) :2257-2267
[37]   Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer [J].
Cheung, Foon-Yiu .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 :13-15
[38]   Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis [J].
Langdahl, Bente ;
Ferrari, Serge ;
Dempster, David W. .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2016, 8 (06) :225-235
[39]   Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma [J].
Jeon, Ha-Lim ;
Oh, In-Sun ;
Baek, Yeon-Hee ;
Yang, Hyowon ;
Park, Jeehye ;
Hong, Soojung ;
Shin, Ju-Young .
JOURNAL OF BONE AND MINERAL METABOLISM, 2020, 38 (02) :254-263
[40]   Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model [J].
Rudnick-Glick, S. ;
Corem-Salkmon, E. ;
Grinberg, I. ;
Margel, S. .
JOURNAL OF NANOBIOTECHNOLOGY, 2016, 14
12345